Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States Across a Decade: 2006 and 2016.

Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, Duncan LR, Sader HS.

Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01566-18. doi: 10.1128/AAC.01566-18. [Epub ahead of print]

PMID:
30373807
2.

Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.

Sader HS, Flamm RK, Streit JM, Carvalhaes CG, Mendes RE.

Int J Infect Dis. 2018 Oct 10;77:82-86. doi: 10.1016/j.ijid.2018.10.004. [Epub ahead of print]

3.

Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints when Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus.

Sader HS, Rhomberg PR, Doyle TB, Flamm RK, Mendes RE.

J Clin Microbiol. 2018 Sep 26. pii: JCM.00777-18. doi: 10.1128/JCM.00777-18. [Epub ahead of print]

4.

Activity of fosfomycin when tested against US contemporary bacterial isolates.

Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Diagn Microbiol Infect Dis. 2018 Aug 28. pii: S0732-8893(18)30304-3. doi: 10.1016/j.diagmicrobio.2018.08.010. [Epub ahead of print]

PMID:
30236530
5.

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.

Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01587-18. doi: 10.1128/AAC.01587-18. [Epub ahead of print]

PMID:
30224535
6.

Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.

Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK.

J Antimicrob Chemother. 2018 Sep 14. doi: 10.1093/jac/dky344. [Epub ahead of print]

PMID:
30219857
7.

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).

Sader HS, Castanheira M, Mendes RE, Flamm RK.

J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.

PMID:
30060117
8.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235.

PMID:
29982565
9.

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M.

J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.

PMID:
29901750
11.

Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.

Deshpande LM, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Sep 1;73(9):2314-2322. doi: 10.1093/jac/dky188.

PMID:
29878213
12.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.

Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00313-18. doi: 10.1128/AAC.00313-18. Print 2018 Aug.

PMID:
29866862
13.

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.

Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00339-18. doi: 10.1128/JCM.00339-18. Print 2018 Aug.

14.
15.

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Sader HS, Dale GE, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00311-18. doi: 10.1128/AAC.00311-18. Print 2018 Jul.

PMID:
29686157
16.

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.

Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2018 Apr 6. doi: 10.1093/jac/dky099. [Epub ahead of print]

PMID:
29659858
17.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.

PMID:
29654893
18.

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia".

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00198-18. doi: 10.1128/AAC.00198-18. Print 2018 Apr. No abstract available.

19.

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):179-183. doi: 10.1016/j.diagmicrobio.2018.01.019. Epub 2018 Feb 24.

PMID:
29571839
20.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.

PMID:
29567128
21.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

PMID:
29563198
22.

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.

Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M.

Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.

PMID:
29510189
23.

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).

Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS.

Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.

PMID:
29410368
24.

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS.

Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.

25.

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Pfaller MA, Huband MD, Shortridge D, Flamm RK.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02327-17. doi: 10.1128/AAC.02327-17. Print 2018 Apr.

26.

Erratum for Pfaller et al., "In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014".

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02383-17. doi: 10.1128/AAC.02383-17. Print 2018 Feb. No abstract available.

27.

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Pfaller MA, Sader HS, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Apr 1;73(4):916-922. doi: 10.1093/jac/dkx485.

PMID:
29294031
28.

Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).

Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2018 Apr;51(4):608-611. doi: 10.1016/j.ijantimicag.2017.12.011. Epub 2017 Dec 23.

PMID:
29277526
29.

Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.

Munson E, Huband MD, Castanheira M, Fedler KA, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):324-328. doi: 10.1016/j.diagmicrobio.2017.11.019. Epub 2017 Dec 5.

PMID:
29276104
30.

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.

Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02397-17. doi: 10.1128/AAC.02397-17. Print 2018 Mar.

31.
32.

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01555-17. doi: 10.1128/AAC.01555-17. Print 2018 Feb.

33.

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):143-147. doi: 10.1016/j.diagmicrobio.2017.10.010. Epub 2017 Oct 19.

PMID:
29157954
34.

The application of in vitro surveillance data for antibacterial dose selection.

Flamm RK, Sader HS, Castanheira M, Jones RN.

Curr Opin Pharmacol. 2017 Oct;36:130-138. doi: 10.1016/j.coph.2017.10.009. Epub 2017 Nov 11. Review.

PMID:
29136540
35.

The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens.

Huang DB, Duncan LR, Flamm RK, Dryden M, Corey GR, Wilcox MH, Torres A, File TM Jr.

Diagn Microbiol Infect Dis. 2018 Jan;90(1):64-66. doi: 10.1016/j.diagmicrobio.2017.09.011. Epub 2017 Sep 20.

36.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

38.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Torre CAM, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Erratum in: Antimicrob Agents Chemother. 2018 Mar 27;62(4):.

39.
40.

In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.

Flamm RK, Rhomberg PR, Sader HS.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01230-17. doi: 10.1128/AAC.01230-17. Print 2017 Dec.

41.

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries.

Pfaller MA, Mendes RE, Streit JM, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2017 Nov 1;72(11):3093-3099. doi: 10.1093/jac/dkx251.

PMID:
28961701
42.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK.

Braz J Infect Dis. 2017 Nov - Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21.

43.

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01045-17. doi: 10.1128/AAC.01045-17. Print 2017 Nov.

44.
45.

Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).

Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.

J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.

PMID:
28735053
46.

Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).

Duncan LR, Sader HS, Smart JI, Flamm RK, Mendes RE.

J Glob Antimicrob Resist. 2017 Sep;10:271-276. doi: 10.1016/j.jgar.2017.03.018. Epub 2017 Jul 19.

PMID:
28735051
47.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.

J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19.

PMID:
28735046
48.

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI, Mendes RE.

Microb Drug Resist. 2017 Sep;23(6):718-726. doi: 10.1089/mdr.2017.0022. Epub 2017 Jul 20.

49.
50.

Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.

Sader HS, Mendes RE, Streit JM, Flamm RK.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01043-17. doi: 10.1128/AAC.01043-17. Print 2017 Sep.

Supplemental Content

Loading ...
Support Center